ENO1 and neoplasm: Wu and colleagues demonstrated that liposomal doxorubicin (LD) conjugated with pHCT74 peptide, which can specifically target to α-enolase (ENO1) on the surface of cancer cells and trigger endocytosis28, exhibits a half maximal inhibitory concentration (IC50) value of about twofold lower than nontargeted LD to colorectal cancer cells (HCT116) in vitro and significantly inhibits tumor growth by 80.1% as compared with nontargeted LD (65.8%) in HCT116-xenografted mice28.